We focused our validation experiments of the in silico determined BORIS target genes on TGFB1, since TGF-beta driven signaling is an important mark of the invasive signature1,4 and TGF-beta acts as tumor promoter at later stages of melanoma tumor development54. This evidence concerns the gene TGFB1 and neoplasm.